米非司酮联合依沙吖啶终止中期妊娠的临床观察

目的:观察米非司酮联合依沙吖啶终止中期妊娠的临床效果及安全性。方法:选择16~26周妊娠要求终止妊娠的妇女200例,随机分成观察组和对照组。两组均经腹壁羊膜腔注射依沙吖啶100mg,观察组同时口服米非司酮50mg,每间隔12h1次,总量为150mg。观察两组引产效果及安全性。结果:两组引产成功率均为100%;观察组注药至宫缩、宫缩至胎儿娩出时间均明显短于对照组(P<0.01);产后2h出血量及胎盘、胎膜残留率明显低于对照组(P<0·05);观察组仅有轻度恶心及头昏等副反应,对照组无明显副反应。结论:米非司酮联合依沙吖啶终止中期妊娠引产时间短、产后出血少、清宫率低,是安全、有效的方法。

Clinical Observation on Mifepristone in Combination with Ethacridine Terminating Intermediate Pregnancy

Objective: To observe the effect and safety of Mifepristone in combination with Ethacridine in terminating intermediate pregnancy. Methods: From 200 patients who had 16-26 weeks pregnancy and asked for abortion were divided into observation group and control group randomly. Women in the observation group took orally total amount of 150mg Mifepristone with 50mg once every other 12 hours after they received injection of 100mg Ethacridine. Women in the control group only received injection of 100mg Ethacridine. Results: The success rates in the two groups were both 100%. In the observation group,the lasting durations beginning at injection to uterine contraction, durations from uterine contraction to childbirth were shorter than both of in the control group (P<0.01). The amount of 2 hours' postpartum hemorrhage and remained rates of placentafetal and membrane in the observation group were all significantly lower than that in the control group(P<0.05). There was no obvious side effects in the observation group. Conclution: Mifepristone in combination with Ethacridine is effective and safe to terminate intermediate pregnancy with no obvious side effects.